---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277556"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:19:34.687881+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Korro Bio Q3 net loss $18.1M; cuts workforce 34%; Novo collaboration paused; KRRO-110 misses functional protein target

## Summary
- Cash, equivalents and securities $102.5M at Sept 30, 2025; net loss $18.1M for Q3.
- Workforce reduction of ~34%; expects one-time restructuring charges of ~$2.4M in Q4 2025.
- KRRO-110 produced functional M-AAT protein but peak total AAT ~10 µM missed protective 11 µM threshold; pivoting to GalNAc construct for AATD.
- Nominated KRRO-121 for hyperammonemia; first-in-human filing anticipated H2 2026.
- Novo Nordisk collaboration paused for 12 months; CMO Dr. Olugemo resigned effective Nov 12.

## SEC filing metadata
- accession: 0001193125-25-277556
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/0001193125-25-277556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/krro-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277556
- JSON: https://secwatch.observer/filing/0001193125-25-277556.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277556.txt

## Source-grounded claims
- claim_id: 410b42a378f58a3cbd5731a2c67271a11f820cb6
  claim: Korro Bio, Inc. announced a restructuring with charges of approximately $2.4 million (approximately 34%).
  evidence_excerpt: On November 12, 2025, Korro implemented a strategic restructuring to extend cash runway, including a workforce reduction of approximately 34%. Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/0001193125-25-277556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.